It’s show-me time for batoclimab, an antibody treatment from Immunovant and Roivant Sciences. Here's what you need to know.

Myasthenia gravis (MG) should be subgrouped into early-onset, late-onset, thymoma, ocular, anti-MuSK, anti-LRP4 and antibody-negative MG. MG has a prevalence of 140 per million, and an annual ...

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...

The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...

Myasthenia gravis, or MG, is "a chronic autoimmune ... Blood tests are also often used to identify associated antibodies. "About 80% of patients with MG are positive" for the antibody behind ...

Abby Smith, 40, a NHS manager from Reading, has the rare autoimmune disease myasthenia gravis, which means she needs her ...

Neonatal myasthenia: A fetus gets certain antibodies from the birthing parent who has myasthenia gravis. An infant may have a weak cry or sucking reflex at birth. These temporary symptoms usually ...

Findings showed nipocalimab plus standard of care (SOC) improved MG-ADL score from baseline by 4.70 points compared with 3.25 points with placebo plus SOC over weeks 22, 23, and 24. The Food and ...

for the treatment of antibody positive (anti-AChR, anti-MuSK, anti-LRP4) patients with generalized myasthenia gravis (gMG), as supported by findings from the Phase 3 Vivacity-MG3 study.

Myasthenia gravis is a serious ... including the approval of Argenx' neonatal FC receptor (FcRn) antibody Vyvgart (efgartigimod alfa). The drug is currently available as an intravenous therapy ...

Myasthenia gravis (MG) should be classified according to antibody status (acetylcholine, MuSK, LRP4, titin), thymus (hyperplasia, neoplasia, atrophy), age at debut (< or >50 years), symptom ...

Johnson & Johnson seeks first EU approval of nipocalimab to treat a broad population of patients living with antibody-positive generalised myasthenia gravis. Available at: https ...